Gut microbiota and metabolites of α-synuclein transgenic monkey models with early stage of Parkinson's disease.

NPJ Biofilms and Microbiomes
yaping yanWei Si

Abstract

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease. However, it is unclear whether microbiota and metabolites have demonstrated changes at early PD due to the difficulties in diagnosis and identification of early PD in clinical practice. In a previous study, we generated A53T transgenic monkeys with early Parkinson's symptoms, including anxiety and cognitive impairment. Here we analyzed the gut microbiota by metagenomic sequencing and metabolites by targeted gas chromatography. The gut microbiota analysis showed that the A53T monkeys have higher degree of diversity in gut microbiota with significantly elevated Sybergistetes, Akkermansia, and Eggerthella lenta compared with control monkeys. Prevotella significantly decreased in A53T transgenic monkeys. Glyceric acid, L-Aspartic acid, and p-Hydroxyphenylacetic acid were significantly elevated, whereas Myristic acid and 3-Methylindole were significantly decreased in A53T monkeys. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (KO0131) and the oxidative phosphorylation reaction (KO2147) were significantly increased in metabolic pathways of A53T monkeys. Our study suggested that the transgenic A53T and α-syn aggregation may affect the intestine microbi...Continue Reading

References

Sep 25, 2004·International Journal of Systematic and Evolutionary Microbiology·Muriel DerrienWillem M de Vos
Jan 30, 2010·Parkinsonism & Related Disorders·Dennis W DicksonJ Eric Ahlskog
Jun 16, 2010·Neuron·Ted M DawsonValina L Dawson
Mar 4, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Alexandra GaenslenDaniela Berg
Feb 22, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·D Salat-FoixO Suchowersky
Mar 9, 2012·Advances in Experimental Medicine and Biology·Sergio PapaVittoria Petruzzella
Aug 28, 2013·Current Opinion in Pharmacology·Vadivel GanapathyNagendra Singh
Dec 11, 2013·Clinical & Developmental Immunology·Wycliffe Omurwa MasantaAndreas E Zautner
Jan 2, 2014·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Cristina Guardia-LaguartaSerge Przedborski
Nov 2, 2014·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Takako UsukiFumio Sakane
Dec 6, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Filip ScheperjansPetri Auvinen
Jan 2, 2015·Human Molecular Genetics·Yuyu NiuXiao-Jiang Li
Jul 17, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Ali KeshavarzianKathleen M Shannon
Jun 10, 2016·Science Translational Medicine·Roberto Di MaioJ Timothy Greenamyre
Oct 14, 2016·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Marthe H R LudtmannAndrey Y Abramov
Apr 13, 2017·Neurobiology of Disease·Emily M RochaLaurie H Sanders
May 17, 2017·Brain Research·Franziska HopfnerGregor Kuhlenbäumer
May 28, 2017·European Journal of Pharmacology·Paula Perez-PardoAletta D Kraneveld
Jun 15, 2017·World Journal of Gastroenterology : WJG·Francois-Pierre MartinAndreas Nydegger
Aug 27, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Per Borghammer
Aug 27, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Anna Heintz-BuschartPaul Wilmes
Nov 15, 2017·Molecular Neurodegeneration·Karim BelarbiMarie-Christine Chartier-Harlin
Dec 9, 2017·ACS Chemical Neuroscience·Cesar de la Fuente-NunezTimothy K Lu
Jan 3, 2018·Journal of Neurogastroenterology and Motility·Arun T NairGopalakrishnan Ramalingam
Feb 27, 2018·Trends in Endocrinology and Metabolism : TEM·Sergej M Ostojic
Mar 5, 2018·Brain, Behavior, and Immunity·Yiwei QianQin Xiao
Dec 24, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Michela BarichellaGianni Pezzoli
May 18, 2019·Nature Communications·Nicholas D YoungblutAndreas H Farnleitner
Jun 30, 2019·Journal of Neuroinflammation·Chin-Hsien LinMing-Shiang Wu
Feb 12, 2020·JAMA : the Journal of the American Medical Association·Melissa J Armstrong, Michael S Okun
Sep 18, 2020·ACS Chemical Neuroscience·Emily KlannVinata Vedam-Mai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.